OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
April 19, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Niklas Adamsson, COO, Envirotainer, suggests how to improve visibility and risk management for cold chain shipping.
In an interview with Pharma Commerce Editor Nicholas Saraceno, Niklas Adamsson, COO, Envirotainer, offers his thoughts on how changing customer needs are affecting cold chain logistics.
Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.
The latest news for pharma industry insiders.
Panel discussion addresses how DE&I can successfully tackle systemic biases and more.
April 18, 2024
Data displayed rapid and sustained B-cell depletion, with 97.2% of study patients with relapsing and primary progressive multiple sclerosis experiencing no relapses.
Session addresses the challenges of implementing autologous/allogeneic cell gene therapies into scalable networks.
A panel uncovers the value in meeting carbon-neutral goals by 2030.
April 17, 2024
Data from the Phase III APPLAUSE-IgAN study showed a 38.3% reduction in proteinuria in patients treated with Fabhalta for IgA nephropathy compared to placebo.